Provided by Tiger Trade Technology Pte. Ltd.

SAB Biotherapeutics, Inc.

2.98
-0.0800-2.61%
Post-market: 3.000.0200+0.67%19:30 EDT
Volume:416.32K
Turnover:1.25M
Market Cap:271.14M
PE:-1.91
High:3.12
Open:3.10
Low:2.96
Close:3.06
52wk High:5.15
52wk Low:1.97
Shares:90.99M
Float Shares:62.04M
Volume Ratio:0.41
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5562
EPS(LYR):-0.7944
ROE:-11.27%
ROA:-33.46%
PB:1.26
PE(LYR):-3.75

Loading ...

SAB Biotherapeutics to present SAB-142 data at ADA Scientific Sessions

Reuters
·
May 29

SAB Biotherapeutics Initiated at Buy by Citigroup

Dow Jones
·
May 22

Citigroup Initiates SAB Biotherapeutics at Buy With $11 Price Target

MT Newswires Live
·
May 22

SAB Biotherapeutics initiated with a Buy at Citi

TIPRANKS
·
May 22

Jefferies Initiates SAB Biotherapeutics at Buy With $11 Price Target

MT Newswires Live
·
May 20

Analysts’ Top Healthcare Picks: Hims & Hers Health (HIMS), SAB Biotherapeutics (SABS)

TIPRANKS
·
May 20

SAB Biotherapeutics initiated with a Buy at Jefferies

TIPRANKS
·
May 20

Analysts Conflicted on These Healthcare Names: Qiagen (QGEN), SAB Biotherapeutics (SABS) and Moderna (MRNA)

TIPRANKS
·
May 14

Chardan Capital Keeps Their Buy Rating on SAB Biotherapeutics (SABS)

TIPRANKS
·
May 13

SAB Biotherapeutics price target raised to $10 from $7 at H.C. Wainwright

TIPRANKS
·
May 13

SAB Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 13

SAB Biotherapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

SAB Biotherapeutics Q1 EPS $(0.35) Misses $(0.20) Estimate.

Benzinga Earnings
·
May 12

Press Release: SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Dow Jones
·
May 12

SAB Biotherapeutics Price Target Maintained With a $13.00/Share by Rodman & Renshaw

Dow Jones
·
May 11

SAB Biotherapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview

Reuters
·
May 08

SAB Biotherapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview

Reuters
·
May 05

SAB Biotherapeutics schedules Q1 2026 earnings call and webcast

Reuters
·
May 05

SAB Biotherapeutics announces annual shareholder meeting

Reuters
·
May 01

Emergent BioSolutions Inc: Executed Agreement Is Valued at Approximately $50 Mln

THOMSON REUTERS
·
Apr 29